Article Text

Download PDFPDF
Efficacy of Trabectedin in Platinum-Sensitive-Relapsed Ovarian Cancer: New Data From the Randomized OVA-301 Study
  1. Nicoletta Colombo, MD
  1. Istituto Europeo di Oncologia, Milan, Italy.
  1. Address correspondence and reprint requests to Nicoletta Colombo, MD, Istituto Europeo di Oncologia, Milan, Italy. E-mail: nicoletta.colombo{at}ieo.it.

Abstract

The results of the OVA-301 study show that trabectedin in combination with pegylated liposomal doxorubicin (PLD) results in improved progression-free survival and response rate in patients with advanced ovarian cancer. The trial has also demonstrated a trend toward improvement in overall survival. A subgroup analysis indicates that in the subset of patients with platinum-free interval (PFI) of 6 to 12 months, the combined treatment resulted in a 6-month improvement in overall survival. Furthermore, in the patients who have received third-line treatment with a platinum agent, it was found that the survival was better in those who had received trabectedin and PLD. These results suggest that prolonging the PFI by a nonplatinum-effective regimen improves the outcome with subsequent, third-line platinum treatment. This strategy may also have positive effects in treatment tolerability, as it allows extra time to recover from platinum-induced toxicities. This hypothesis is currently been tested in the INOVATYON (INternational OVArian Cancer Patients Trial With YONdelis) phase III study.

  • Trabectedin
  • Relapsed ovarian cancer

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Disclosure: Editorial assistance for the preparation of this manuscript was funded by PharmarMar.